BR112022008095A2 - Métodos e composições para o tratamento da síndrome de rett - Google Patents
Métodos e composições para o tratamento da síndrome de rettInfo
- Publication number
- BR112022008095A2 BR112022008095A2 BR112022008095A BR112022008095A BR112022008095A2 BR 112022008095 A2 BR112022008095 A2 BR 112022008095A2 BR 112022008095 A BR112022008095 A BR 112022008095A BR 112022008095 A BR112022008095 A BR 112022008095A BR 112022008095 A2 BR112022008095 A2 BR 112022008095A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- compositions
- treatment
- rett syndrome
- syndrome
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Detergent Compositions (AREA)
- Chemical Or Physical Treatment Of Fibers (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962927008P | 2019-10-28 | 2019-10-28 | |
| US202063031201P | 2020-05-28 | 2020-05-28 | |
| PCT/US2020/057627 WO2021086892A1 (en) | 2019-10-28 | 2020-10-28 | Methods and compositions for treatment of rett syndrome |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022008095A2 true BR112022008095A2 (pt) | 2022-07-12 |
Family
ID=75715568
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022008095A BR112022008095A2 (pt) | 2019-10-28 | 2020-10-28 | Métodos e composições para o tratamento da síndrome de rett |
Country Status (14)
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023287750A1 (en) | 2021-07-12 | 2023-01-19 | Acadia Pharmaceuticals Inc. | Crystalline forms of trofinetide |
| WO2023242844A1 (en) * | 2022-06-15 | 2023-12-21 | Ramot At Tel-Aviv University Ltd. | Method and therapeutic agent for treatment of disease or disorder associated with impaired firing rate and/or mitochondrial calcium homeostasis |
| WO2025262646A1 (en) * | 2024-06-22 | 2025-12-26 | Biophore India Pharmaceuticals Pvt. Ltd | Dosage forms of trofinetide and its pharmaceutically acceptable salt thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6709817B1 (en) * | 1999-09-07 | 2004-03-23 | Baylor College Of Medicine | Method of screening Rett syndrome by detecting a mutation in MECP2 |
| LT2667715T (lt) * | 2011-01-27 | 2017-11-10 | Neuren Pharmaceuticals Limited | Autizmo spektro susirgimų gydymas, naudojant glicil-l-2-metilprolil-l-glutamo rūgštį |
| CN105358160A (zh) * | 2013-02-20 | 2016-02-24 | 瑟阿瓦斯克公司 | 亚硝酸盐的药物制剂及其用途 |
| SI3024463T1 (sl) * | 2013-07-25 | 2020-08-31 | Neuren Pharmaceuticals Limited | Nevroprotektivne biciklične spojine in postopki za njihovo uporabo pri zdravljenju motenj avtističnega spektra in nevrorazvojnih motenj |
| US20150224164A1 (en) * | 2013-11-26 | 2015-08-13 | Neuren Pharmaceuticals Limited | Treatment of autism spectrum disorders using glycyl-l-2-methylprolyl-l-glumatic acid |
| GB2554064B (en) * | 2016-09-01 | 2019-11-20 | Jit Singh Shailinder | An enteral feeding tube |
-
2020
- 2020-10-28 KR KR1020227018117A patent/KR20220106982A/ko active Pending
- 2020-10-28 WO PCT/US2020/057627 patent/WO2021086892A1/en not_active Ceased
- 2020-10-28 JP JP2022552123A patent/JP2022553888A/ja active Pending
- 2020-10-28 AU AU2020376801A patent/AU2020376801A1/en active Pending
- 2020-10-28 CA CA3156680A patent/CA3156680A1/en active Pending
- 2020-10-28 CN CN202080090500.2A patent/CN115335071A/zh active Pending
- 2020-10-28 TW TW109137417A patent/TW202116300A/zh unknown
- 2020-10-28 MX MX2022004785A patent/MX2022004785A/es unknown
- 2020-10-28 EP EP20883589.2A patent/EP4051308A4/en active Pending
- 2020-10-28 IL IL292617A patent/IL292617B2/en unknown
- 2020-10-28 BR BR112022008095A patent/BR112022008095A2/pt unknown
-
2022
- 2022-02-01 US US17/590,496 patent/US20220339138A1/en active Pending
- 2022-04-28 CL CL2022001079A patent/CL2022001079A1/es unknown
- 2022-05-31 CO CONC2022/0007501A patent/CO2022007501A2/es unknown
-
2025
- 2025-07-10 JP JP2025116586A patent/JP2025148461A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2025148461A (ja) | 2025-10-07 |
| AU2020376801A1 (en) | 2022-06-09 |
| IL292617B1 (en) | 2025-11-01 |
| WO2021086892A1 (en) | 2021-05-06 |
| TW202116300A (zh) | 2021-05-01 |
| CA3156680A1 (en) | 2021-05-06 |
| US20220339138A1 (en) | 2022-10-27 |
| IL292617A (en) | 2022-07-01 |
| CO2022007501A2 (es) | 2022-08-30 |
| EP4051308A4 (en) | 2023-08-23 |
| EP4051308A1 (en) | 2022-09-07 |
| IL292617B2 (en) | 2026-03-01 |
| KR20220106982A (ko) | 2022-08-01 |
| JP2022553888A (ja) | 2022-12-26 |
| CL2022001079A1 (es) | 2023-04-21 |
| CN115335071A (zh) | 2022-11-11 |
| MX2022004785A (es) | 2022-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022015151A2 (pt) | Método para reduzir ou prevenir progressão de um tumor ou tratar câncer, e, composição | |
| BR112022012637A2 (pt) | Composto de piridazinil-tiazolcarboxamida, composição farmacêutica e inibidor da dgk ¿ que compreendem o mesmo e uso do dito composto para tratar câncer relacionado à ativação das células imunes ou câncer tendo resistência à terapia com anticorpo anti-pd-1 / anticorpo anti-pd-l1 | |
| MX2021015338A (es) | Composicion que comprende pridopidina y un analogo de la misma para el tratamiento de la enfermedad de huntington y sintomas de la misma. | |
| BR112019005930A2 (pt) | combinações compreendendo um inibidor de ssao/vap-1 e um inibidor de sglt2, e usos das mesmas | |
| MX2025001920A (es) | Tratamiento de enfermedades y trastornos asociados a las mitocondrias, incluyendo los sintomas de los mismos usando pridopidina | |
| BR112023001143A2 (pt) | Conjugado, composto, composição farmacêutica, métodos para tratar uma doença e reduzir o nível de uma proteína brm alvo em um indivíduo | |
| BR112014004845A2 (pt) | pelo menos uma entidade química; pelo menos um composto; composição farmacêutica; uso de uma quantidade terapeuticamente eficaz de pelo menos uma entidade química; composição farmacêutica embalada | |
| BRPI0819690B8 (pt) | uso de uma composição compreendendo cisteamina ou cistamina, ou um sal farmaceuticamente aceitável das mesmas | |
| BR112013010556A2 (pt) | métodos e composições adequadas para a promoção de uma pele saudável | |
| BR112021019262A2 (pt) | Uso de ciclo-his-pro (chp) para prevenir, atenuar ou tratar fibrose | |
| BR112023021131A2 (pt) | Tratamento de tremor essencial | |
| BR112017006272A2 (pt) | composição farmacêutica para tratar colite ulcerativa. | |
| MX2021003681A (es) | Composiciones y metodos para el tratamiento de desordenes inflamatorios. | |
| BR112022015800A2 (pt) | Tratamento de colangite biliar primária com elafibranor | |
| BR112022018396A2 (pt) | Método de tratamento ou prevenção para insuficiência cardíaca crônica | |
| CO2022007501A2 (es) | Métodos y composiciones para el tratamiento del síndrome de rett | |
| MX389282B (es) | Composiciones y métodos para tratar sinucleinopatías. | |
| BR112022001395A2 (pt) | Métodos para administrar anticorpos anti-siglec-8 e corticosteroides | |
| BR112023000598A2 (pt) | Composições de dose oral unitária composta de ibuprofeno e famotidina para o tratamento da dor aguda e redução da gravidade e/ou risco de azia | |
| MX2020013692A (es) | Compuestos de pirazol e imidazol para la inhibicion de il-17 y rorgamma. | |
| BR112017024073A2 (pt) | métodos e composições para a inibição da via egf/egfr em combinação com inibidores de tirosina quinase | |
| BR112022018166A2 (pt) | Medicamento para tratamento e/ou prevenção de câncer, agentes que aumentam a eficácia de droga de uma composição farmacêutica e método para tratar e/ou prevenir câncer | |
| BR112015029709A2 (pt) | dihidroetorfina para o fornecimento de alívio da dor e anestesia | |
| BR112023023534A2 (pt) | Composição farmacêutica para uso no tratamento de infarto cererbral | |
| BR112017019480A2 (pt) | dosagem unitária de composição vitamínica ampliável, e, método para tratar uma deficiência de vitamina lipossolúvel. |